| Drug Name: | Letrozole (112809-51-5) |
|---|---|
| PubChem ID: | 3902 |
| SMILES: | C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3 |
| InchiKey: | HPJKCIUCZWXJDR-UHFFFAOYSA-N |
| Therapeutic Category: | Antineoplastic Agents, Aromatase Inhibitors, Enzyme Inhibitors, Estrogen Antagonists, Hormone Antagonists, Hormones |
| Molecular Weight (dalton) | : | 285.31 |
| LogP | : | 2.65916 |
| Ring Count | : | 3 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 78.29 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Cardiovascular Disease | Adenylate kinase (P00568) | Total suppression of aromatase by letrozole may have adverse effects of cardiovascular disease. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Osteoporosis | Adenylate kinase (P00568) | Total suppression of aromatase by letrozole may have adverse effects of increased osteoporosis [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
| Urogenital Atrophy | Adenylate kinase (P00568) | Total suppression of aromatase by letrozole may have adverse effects of urogenital atrophy. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category